MX358501B - Combinación farmacéutica de sinergia para el tratamiento del carcinoma de célula escamosa de cabeza y cuello. - Google Patents
Combinación farmacéutica de sinergia para el tratamiento del carcinoma de célula escamosa de cabeza y cuello.Info
- Publication number
- MX358501B MX358501B MX2013014071A MX2013014071A MX358501B MX 358501 B MX358501 B MX 358501B MX 2013014071 A MX2013014071 A MX 2013014071A MX 2013014071 A MX2013014071 A MX 2013014071A MX 358501 B MX358501 B MX 358501B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- cell carcinoma
- squamous cell
- neck
- head
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se relaciona con una combinación farmacéutica para uso en el tratamiento contra el carcinoma de célula escamosa, comprende un inhibidor CDK seleccionado de los compuestos de la fórmula (I) o una sal farmacéuticamente aceptable del mismo y uno o más agentes antineoplásticos seleccionados de sorafenib, lapatinib, erlotinib, Cisplatinaa, 5-fluorouracel, docetael o cetuximab o una sal farmacéuticamente aceptable del mismo. La combinación farmacéutica presenta sinergia cuando cuando se utiliza en el tratamiento del carcinoma de célula escamosa. Esta invención se relaciona con una composición farmacéutica que comprende tal combinación y un método para el tratamiento del carcinoma de célula escamosa de cabeza y cuello (SCCHN), utilizando una cantidad terapéuticamente efectiva del tal combinación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161491569P | 2011-05-31 | 2011-05-31 | |
PCT/IB2012/052698 WO2012164497A1 (en) | 2011-05-31 | 2012-05-30 | A synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013014071A MX2013014071A (es) | 2014-05-28 |
MX358501B true MX358501B (es) | 2018-08-23 |
Family
ID=46551791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014071A MX358501B (es) | 2011-05-31 | 2012-05-30 | Combinación farmacéutica de sinergia para el tratamiento del carcinoma de célula escamosa de cabeza y cuello. |
Country Status (16)
Country | Link |
---|---|
US (4) | US20140112918A1 (es) |
EP (1) | EP2714031B1 (es) |
JP (1) | JP2014515394A (es) |
KR (1) | KR20140056190A (es) |
CN (1) | CN103561734B (es) |
AR (1) | AR086625A1 (es) |
AU (1) | AU2012264246A1 (es) |
BR (1) | BR112013030820A2 (es) |
CA (1) | CA2837042C (es) |
DK (1) | DK2714031T3 (es) |
ES (1) | ES2682270T3 (es) |
IL (1) | IL229601A0 (es) |
MX (1) | MX358501B (es) |
RU (1) | RU2013158914A (es) |
TW (1) | TW201300105A (es) |
WO (1) | WO2012164497A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201300105A (zh) * | 2011-05-31 | 2013-01-01 | Piramal Life Sciences Ltd | 治療頭頸鱗狀細胞癌之相乘藥物組合物 |
CN117731786A (zh) | 2013-07-12 | 2024-03-22 | 皮拉马尔企业有限公司 | 用于治疗黑素瘤的药物组合 |
US10555931B2 (en) | 2014-05-28 | 2020-02-11 | Piramal Enterprises Limited | Pharmaceutical combination for the treatment of cancer |
KR102275758B1 (ko) * | 2016-03-28 | 2021-07-12 | 프레시지 바이오싸이언시스, 인크. | 암 치료를 위한 제약학적 조합물 |
RU2711308C1 (ru) * | 2019-07-13 | 2020-01-16 | Михаил Сергеевич Ольшанский | Способ паллиативного лечения рецидивов плоскоклеточного рака головы и шеи |
TW202317128A (zh) * | 2021-06-10 | 2023-05-01 | 大陸商上海岸闊醫藥科技有限公司 | 治療化療相關的胃腸道副作用的化合物和方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN164232B (es) | 1986-04-11 | 1989-02-04 | Hoechst India | |
USH1427H (en) | 1988-04-06 | 1995-04-04 | Briet; Phillipe | Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2 |
US5116954A (en) | 1988-04-06 | 1992-05-26 | Lipha, Lyonnaise Industrielle Pharmaceutique | Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety |
US5284856A (en) | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
US5723313A (en) | 1995-09-27 | 1998-03-03 | St. Jude Children's Research Hospital | ARF-p19, a novel regulator of the mammalian cell cycle |
US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
CN100355751C (zh) | 2000-03-29 | 2007-12-19 | 西克拉塞尔有限公司 | 2-取代的4-杂芳基-嘧啶、其组合物及其用途 |
JP2004501191A (ja) | 2000-06-28 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | カルベジロール |
US7915301B2 (en) | 2002-07-08 | 2011-03-29 | Piramal Life Science Limited | Inhibitors of cyclin dependent kinases and their use |
US7271193B2 (en) | 2002-07-08 | 2007-09-18 | Nicholas Piramal India, Ltd. | Inhibitors of cyclin-dependent kinases and their use |
US7884127B2 (en) * | 2002-07-08 | 2011-02-08 | Pirimal Life Sciences Ltd. | Inhibitors of cyclin dependent kinases and their use |
TWI331034B (en) * | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
EP1558289A1 (en) | 2002-11-06 | 2005-08-03 | Cyclacel Limited | Pharmaceutical composition comprising a cdk inhibitor and gemcitabine |
GB0328180D0 (en) | 2003-12-04 | 2004-01-07 | Cyclacel Ltd | Combination |
WO2005055952A2 (en) | 2003-12-08 | 2005-06-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Synergistic anti-cancer compositions |
JP2008533039A (ja) | 2005-03-11 | 2008-08-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 抗アポトーシスBcl−2ファミリーメンバーのクロメン−4−オン阻害剤およびその使用 |
CA2655789C (en) * | 2006-06-21 | 2014-04-01 | Piramal Life Sciences Limited | Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation |
GB0706633D0 (en) | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
CA2687204C (en) | 2007-05-15 | 2015-11-24 | Piramal Life Sciences Limited | A synergistic pharmaceutical combination for the treatment of cancer |
US20090030005A1 (en) * | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combinations for the treatment of cancer |
TWI461194B (zh) * | 2009-05-05 | 2014-11-21 | Piramal Entpr Ltd | 吡咯啶取代黃酮作為輻射致敏劑 |
WO2011063309A1 (en) * | 2009-11-20 | 2011-05-26 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
TW201300105A (zh) * | 2011-05-31 | 2013-01-01 | Piramal Life Sciences Ltd | 治療頭頸鱗狀細胞癌之相乘藥物組合物 |
-
2012
- 2012-05-29 TW TW101119157A patent/TW201300105A/zh unknown
- 2012-05-30 JP JP2014513295A patent/JP2014515394A/ja active Pending
- 2012-05-30 CN CN201280025945.8A patent/CN103561734B/zh active Active
- 2012-05-30 US US14/122,922 patent/US20140112918A1/en not_active Abandoned
- 2012-05-30 MX MX2013014071A patent/MX358501B/es active IP Right Grant
- 2012-05-30 KR KR1020137034990A patent/KR20140056190A/ko not_active Application Discontinuation
- 2012-05-30 BR BR112013030820A patent/BR112013030820A2/pt not_active IP Right Cessation
- 2012-05-30 WO PCT/IB2012/052698 patent/WO2012164497A1/en active Application Filing
- 2012-05-30 CA CA2837042A patent/CA2837042C/en active Active
- 2012-05-30 DK DK12738184.6T patent/DK2714031T3/en active
- 2012-05-30 RU RU2013158914/15A patent/RU2013158914A/ru not_active Application Discontinuation
- 2012-05-30 AU AU2012264246A patent/AU2012264246A1/en not_active Abandoned
- 2012-05-30 ES ES12738184.6T patent/ES2682270T3/es active Active
- 2012-05-30 EP EP12738184.6A patent/EP2714031B1/en active Active
- 2012-05-31 AR ARP120101925A patent/AR086625A1/es unknown
-
2013
- 2013-11-25 IL IL229601A patent/IL229601A0/en unknown
-
2016
- 2016-07-08 US US15/206,185 patent/US10245251B2/en active Active
-
2019
- 2019-02-08 US US16/270,643 patent/US10980776B2/en active Active
-
2021
- 2021-03-15 US US17/201,614 patent/US20210196680A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20140112918A1 (en) | 2014-04-24 |
WO2012164497A1 (en) | 2012-12-06 |
EP2714031A1 (en) | 2014-04-09 |
CN103561734A (zh) | 2014-02-05 |
US10245251B2 (en) | 2019-04-02 |
NZ619488A (en) | 2015-09-25 |
JP2014515394A (ja) | 2014-06-30 |
BR112013030820A2 (pt) | 2016-12-06 |
CA2837042A1 (en) | 2012-12-06 |
TW201300105A (zh) | 2013-01-01 |
US20190167639A1 (en) | 2019-06-06 |
US10980776B2 (en) | 2021-04-20 |
US20210196680A1 (en) | 2021-07-01 |
US20170157090A1 (en) | 2017-06-08 |
RU2013158914A (ru) | 2015-07-10 |
ES2682270T3 (es) | 2018-09-19 |
MX2013014071A (es) | 2014-05-28 |
DK2714031T3 (en) | 2018-08-06 |
AR086625A1 (es) | 2014-01-08 |
CN103561734B (zh) | 2017-07-11 |
AU2012264246A1 (en) | 2014-01-09 |
EP2714031B1 (en) | 2018-05-23 |
KR20140056190A (ko) | 2014-05-09 |
CA2837042C (en) | 2018-12-11 |
IL229601A0 (en) | 2014-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
MX2013014071A (es) | Combinacion de tratamiento de sinergia para el tratamiento del carcinoma de celula escamosa de cabeza y cuello. | |
PH12015500719A1 (en) | Gdf-8-inhibitors | |
MX369385B (es) | Productos para cicatrizar heridas tisulares. | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
EA201290859A1 (ru) | Лечение люпус-артрита с использованием лаквинимода | |
MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
MX2013012588A (es) | Inhibidores de cinasa. | |
MX2018009173A (es) | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash). | |
SG10201810404XA (en) | Combination comprising a glucocorticoid and edo-s101 | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
EP2796450A4 (en) | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES | |
WO2012161497A3 (ko) | 보습능이 우수한 펩타이드 유도체 및 이의 용도 | |
MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
BR112014010729A2 (pt) | métodos para tratamento de ataques de gota | |
WO2010019701A3 (en) | Diaryl urea derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |